DrugPatentWatch Database Preview

Details for Patent: 10,195,214

« Back to Dashboard

Which drugs does patent 10,195,214 protect, and when does it expire?

Patent 10,195,214 protects KORLYM and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 10,195,214

Title:	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Abstract:	Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions. Applicant has surprisingly found that GRAs may be administered to subjects receiving CYP3A inhibitors or steroidogenesis inhibitors such as ketoconazole without increasing risk adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole (a CYP3A inhibitor and a steroidogenesis inhibitor), providing safe concomitant administration of the GRA and ketoconazole. In embodiments, the GRA dose may be reduced.
Inventor(s):	Belanoff; Joseph K. (Menlo Park, CA)
Assignee:	Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:	15/627,359
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,195,214
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 10,195,214
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,195,214

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012		RX	Yes	Yes						TREATING CUSHING'S SYNDROME

International Family Members for US Patent 10,195,214

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2018160775